insights_auto
Why is 084990 down 2.70%?
Dive Deeperchevron_right
084990:KOSDAQ
Helixmith Co Ltd
â‚©3,970.00
arrow_downward
-2.70%(-110.00) 1D
Oct 19, 3:30:14 PM GMT+9 · KRW
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 084990...
Open
â‚©3,985
High
â‚©4,230
Low
â‚©3,890
Mkt. cap
182.99B
Avg. vol.
388.21K
Volume
329.43K
52-wk high
â‚©9,960
52-wk low
â‚©2,725
EPS
-â‚©35
Shares outstanding
46.09M
No. of employees
38
Open
â‚©3,985
High
â‚©4,230
Low
â‚©3,890
Mkt. cap
182.99B
Avg. vol.
388.21K
Volume
329.43K
52-wk high
â‚©9,960
52-wk low
â‚©2,725
EPS
-â‚©35
Shares outstanding
46.09M
No. of employees
38
News stories
From web sources and news partners
investingLive
·
41 minutes ago
Nasdaq and S&P rebounds; Dow slips
TradingView
·
38 minutes ago
The Dow Jones Index Closes 0.07% Lower
Traders Union
·
34 minutes ago
Sherwin-Williams rebound signals improving momentum for Dow stock
Investing.com
·
37 minutes ago
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.07%
Profile
Helixmith Co. LTD. is a biotechnology company located in Seoul, South Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis, currently in phase III diabetic peripheral neuropathy in the US. Engensis is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor, HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers, amyotrophic lateral sclerosis, coronary artery disease, claudication, and Charcot-Marie-Tooth disease. Wikipedia
About Helixmith Co Ltd